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Acute intermittent porphyria (AIP), the most common 
porphyria affecting the nervous system, typically 
presents with neurovisceral crises followed by a motor 
neuropathy. We describe an unusual presentation in a 
young man with molecularly confirmed AIP.
Case presentation
A 23-year-old university student was referred to Groote Schuur Hospital, 
Cape Town, South Africa, with suspected motor neuron disease. Over 
the preceding year he had noticed insidious progressive weakness of both 
upper limbs. Initially, the weakness affected grip strength bilaterally, but 
within 9 months progressed to also involve proximal arm function. Ten 
months after onset, he developed profound leg weakness over a period of 
days, rendering him unable to walk without support. He had no bowel or 
bladder sphincter involvement and no bulbar symptoms, but complained 
of a weak cough. He had not experienced any neuropsychiatric symptoms 
or abdominal pain.
Examination showed a thin and wasted man with marked 
amyotrophy involving all four limbs, both proximally and distally 
(Fig. 1). He was bed-bound, and unable to turn in bed, feed or 
dress himself. He had mild symmetrical facial weakness and a weak 
cough with a reduced vital capacity (<80% of expected). He had 
truncal weakness and a flaccid quadriparesis, but no fasciculations 
were noted: upper limb strength Medical Research Council (MRC) 
grade 1/5 proximal, 2/5 distal; lower limb strength 2/5 proximal, 
3/5 distal. He was areflexic in the legs with either hyporeflexia 
(biceps and supinator reflexes) or areflexia (triceps reflexes) in the 
arms. Findings on sensory examination were normal apart from 
a patch of reduced sensibility for pinprick and touch over the left 
anteromedial thigh region.
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Acute intermittent porphyria, the most common porphyria affecting the nervous system, typically presents with neurovisceral crises 
followed by a motor neuropathy. We describe a 23-year-old black South African man presenting with a progressive stuttering, lower 
motor neuron syndrome developing over months. He had not experienced pain or neuropsychiatric symptoms. One year after symptom 
onset he was bed-bound with a flaccid quadriparesis. There was marked amyotrophy, but without fasciculations. Sensation was intact 
apart from a hypo-aesthetic patch over the thigh. Electrophysiological investigations showed an active motor axonopathy. Urinary 
porphyrins, δ-aminolaevulinic acid and porphobilinogen were elevated. Mutation analysis revealed the c445C>T (R149X) mutation in 
the porphobilinogen deaminase gene. The patient responded dramatically to haem arginate and could walk with assistance 2 weeks later. 
We identified the first molecularly confirmed acute intermittent porphyria in a black South African. The clinical presentation mimicked a 
progressive lower motor neuron syndrome.
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Fig. 1. (A) Upper limbs showing marked wasting of both proximal and distal muscles with  attening of forearms in the anteroposterior plane. (B) Lower limbs 
showing marked wasting of proximal and distal muscles with bilateral foot drop. (C) Dorsal aspect of right hand showing wasting of thenar and hypothenar 
muscles, and ulnar clawing.
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The following tests were either normal or negative: full blood 
count, renal function and electrolytes, liver profile, erythrocyte 
sedimentation rate, fasting glucose, γ-globulin electrophoresis, serum 
lead levels, HIV and syphilis serology. The cerebrospinal fluid 
was acellular with normal chemistry. Nerve conduction studies 
demonstrated a motor axonopathy in all four limbs with normal 
sensory responses. Electromyography studies of proximal and distal 
limb muscles showed denervation with fibrillation potentials in 
keeping with an active neurogenic process.
This unusual and severe motor neuropathy, but without 
fasciculations and a with single patch of numbness, prompted a 
porphyria screen. It was strongly positive with a δ-aminolaevulinic 
acid (ALA) level of 678 μmol/10 mmol creatinine (upper limit 
of reference range ≤45) and a porphobilinogen (PBG) level of 
1 477 μmol/10 mmol creatinine (upper limit of reference range 
≤16). Plasma porphyrin fluoroscanning demonstrated an emission 
peak at a wavelength of 619 nm (excitation wavelength 405 nm). 
This pattern, together with urinary ALA and PBG characterisation, 
was compatible with a diagnosis of AIP. His urinary porphyrin 
excretion profile showed greatly elevated porphyrin concentrations 
(10- to 13-fold) with a preponderance of uroporphyrin, typical of 
acute porphyria. The diagnosis of AIP was confirmed by identifying 
the R149X mutation, c445C>T in exon 9 by sequencing the PBG 
deaminase gene (also known as hydroxymethylbilane synthase).
On additional questioning it became evident that 4 months 
after symptom onset, he had experienced paraesthesiae over both 
thighs and buttocks. This resolved partially over days with residual 
numbness over his left anterior thigh. Also, over the preceding 3 
years he had had intermittent episodes of constipation, at times even 
requiring hospitalisation for laxative treatment. 
Clinical course
The patient was treated with standard dosage intravenous haem 
arginate (Normosang), a formulation of haematin, for 6 days. He 
started improving within 3 days of treatment initiation and was able 
to turn in bed and hold his mobile phone to his ear. After 2 weeks 
he was able to stand and mobilise with assistance; both shoulder 
abduction and hip flexion had improved by at least one grade 
(shoulder 4/5; hip ≥3/5). The distal power remained unchanged. 
Over the following 6 months, our patient re-presented twice with 
relapses: on one occasion characterised by abdominal pain and 
constipation; and on the other with only worsening hand weakness 
and constipation. Further courses of intravenous haem arginate were 
administered with resolution of abdominal pain and improvement in 
distal arm strength. He still has weak intrinsic hand muscles (MRC 
2/5), but lives independently. 
Discussion
We report an unusual presentation of AIP in a young black South 
African man with a chronic progressive, albeit stuttering, presentation 
of extensive proximal and distal muscle wasting and weakness 
developing over the course of 1 year, masquerading as a lower motor 
neuron syndrome. Our case was atypical in that there were no overt 
episodes of severe abdominal pain or neuropsychiatric symptoms 
throughout the course of the illness. A history of recurrent bouts 
of constipation, probably reflecting the autonomic neuropathy of 
AIP, was only obtained retrospectively once the diagnosis had been 
established. 
AIP is a dominantly inherited condition resulting from the 
deficiency of PBG deaminase, which leads to markedly elevated 
urinary ALA and PBG during an acute attack. Urinary porphyrins 
are also frequently raised. It is the most common and typically most 
severe of the acutely presenting porphyrias.[1] The older literature 
on the neurological manifestations of AIP tends to emphasise 
the classic triad of abdominal pain, neuropathy and psychosis.[2,3] 
Autonomic nervous involvement may manifest with tachycardia, 
fluctuating blood pressure and abdominal pain secondary to ileus. [1] 
The neuropathy usually follows a few days later, with maximum 
deficit typically reached over 1 month.[1] Characteristically, the 
neuropathy of AIP is a predominantly motor neuropathy with a 
predilection for upper limb involvement and proximal more than 
distal weakness. Unusual sensory symptoms sometimes occur in a 
bathing trunk distribution.[1] 
It is held that the neuropathy associated with AIP usually 
resolves slowly over months and recovery depends on the extent 
and magnitude of axonal degeneration.[1] Reports have documented 
gradual improvement of muscle strength over months[4] to years, but 
up to 50% of patients may have residual weakness[5] and 4% remain 
quadriparetic. [6] However, fairly rapid improvement on haem arginate, 
similar to that which our patient experienced, has been observed in 
several cases.[7,8] The dramatic clinical recovery observed in our patient’s 
proximal muscles over a few days argues for a substantial contribution 
from neural dysfunction rather than neural degeneration.
The exact mechanism whereby AIP causes neurotoxicity is 
uncertain, although it has been postulated that ALA (or other 
metabolites) which are produced in excess by the liver, are 
neurotoxic.[3,9] This is supported by the benefit seen following 
liver transplantation in patients with severe AIP.[3] In addition, 
ALA-induced oxidative damage has been demonstrated in animal 
models,[10] and ALA levels are also significantly increased in lead 
poisoning, which may produce a porphyria-like neuropathy.[1] 
As a critical component of mitochondrial cytochromes, haem 
participates in the electron transport chain and adenosine 
triphosphate (ATP) production. Fast axonal transport is highly 
dependent on this energy.[9] Haem deficiency may result in Na+/
K+ pump failure, altered membrane potential with consequent 
neuronal injury, and even axonal death.[11] 
Acute attacks of AIP are precipitated by triggers that either directly 
induce hepatic ALA synthase 1 (ALAS1) activity, or increase the 
demand for haem synthesis, thereby reducing the negative feedback 
on ALAS1.[3] These events include menstrual hormonal changes, 
fasting, smoking, infections, and exposure to porphyrinogenic 
drugs. Haematin therapy temporarily down-regulates hepatic ALAS1 
activity, thereby reducing the overproduction of potentially neurotoxic 
metabolites by the liver.[1,3] Symptom onset in our patient correlated 
with his student life, which included erratic meals and alcohol 
binges. However, relapses following the diagnosis and counselling 
did not have clear precipitants, although relative undernutrition 
may have contributed. The absence of clearly defined clinical attacks 
in our patient complicates future treatment decisions, especially as 
porphyrin levels and clinical status do not correlate well.[12]
Conclusion
While AIP is known to exist in all racial groups, it remains a poorly 
diagnosed and documented condition in black Africans, with only 
a few PBG deaminase gene defects reported.[13] The PBG deaminase 
c445C>T (R149X) mutation in our patient is novel in a black African. 
This case illustrates the need to consider AIP as a possible cause 
of a progressive severe predominantly motor neuropathy, even in the 
apparent absence of other features associated with hepatic porphyria. 
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